447 articles with MorphoSys AG
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
Galapagos NV and MorphoSys AG announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement with Novartis Pharma AG, entered into on July 19, 2018, for the development and commercialization of their joint program MOR106 (the Collaboration Agreement).
MorphoSys AG announced today that its shares will be included in the MDAX as of September 24, 2018 as announced by Deutsche Börse.
On August 8, 2018 Beijing time I-Mab Biopharma and MorphoSys AG announced today that I-Mab has Submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma.
7/30/2018Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.
Galapagos and MorphoSys signed an exclusive development and commercialization deal with Swiss-based Novartis.
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
BlackThorn Therapeutics today announced the appointment of a key strategic executive to the company’s board of directors, George S. Golumbeski, Ph.D.
Celgne's head of business development, George Golumbeski, has also left the company.
Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
Galapagos NV and MorphoSys AG announced today that the first patient has been screened in IGUANA, a Phase 2 study with MOR106.
Only days after UK-based Mereo BioPharma canceled its plans for an initial public offering (IPO) on the Nasdaq Global Market, Framingham, Massachusetts-based Alzheon dropped its IPO plans.
MorphoSys AG announced that an affiliate of its licensee, Janssen Korea Ltd. (Janssen), reported that South Korea's Ministry of Food and Drug Safety has approved Tremfya(R) (guselkumab) for the treatment of moderate to severe adult plaque psoriasis requiring phototherapy or systemic therapies.
Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.
MorphoSys, a Germany-based biopharmaceutical company, is aiming for a listing on the Nasdaq exchange hoping to secure approximately $150 million.
MorphoSys will present at the following conferences.
MorphoSys Presents Clinical Data on MOR208 plus Lenalidomide in Aggressive Lymphoma (R/R DLBCL) at ASH 2017 Conference
MorphoSys today presented clinical data from the ongoing phase 2 clinical trial evaluating MOR208 in combination with lenalidomide in patients with relapsed or R/R DLBCL.
Please note MorphoSys AG's financial reporting dates 2018 as follows...
MorphoSys Announces That its Licensee Janssen Has Received Approval for Tremfya (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Canada
Janssen's Tremfya is now approved in the U.S., Canada and the European Union
Under the terms of the agreement, I-Mab will assume exclusive responsibility for all subsequent development and commercialization of MOR202 in the agreed territory.
MorphoSys to receive a USD 20 million upfront payment and entitled to tiered, double digit royalties on net sales of MOR202 plus milestone payments of up to USD 100 million from I-Mab
MorphoSys Announces That its Licensee Janssen Has Received Approval for Tremfya (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis
MorphoSys is eligible to receive royalties on net sales of Tremfya.